Since kringle (K)5, not present in the angiostatin molecule, was shown to be a key functional domain possessing potent antiangiogenic activity, we have evaluated a new plasminogen-derived fragment, consisting of the N-terminal part of human plasminogen, that included the complete secondary structure of K1-5 (aa 1-566). In contrast to other fragments described to date, K1-5 includes cysteine residues at positions 543, 555 and 560 allowing the formation of the three disulfide bonds lying within K5. Vascular endothelial cell proliferation and migration assays revealed that a replication-defective adenovirus (AdK1-5(1-566)), expressing K1-5 (aa 1-566), was dose dependently more potent that AdK1-3(1-354), an adenovirus that expresses only the first three kringles. In contrast to AdK1-3(1-354), a single intratumoral injection of AdK1-5(1-566) into MDA-MB-231 breast human carcinoma tumors was followed by a total regression of 40% of the tumor and by significant arrest of tumor growth (90%), which was correlated with a drastic decrease of functional neovascularization into the tumors. Furthermore, systemic delivery of AdK1-5(1-566) in mice inhibited the lung invasion of melanoma B16-F10 cells by 87%. Our findings provide evidence that the full kringles of plasminogen (aa 1-566) may be much more potent than K1-3 (aa 1-354), for the suppression of angiogenesis, tumor growth and metastatic dissemination. Gene Therapy (2005) 12, 831-842.
Introduction
Angiogenesis is defined as the formation of new blood vessels that sprout from pre-existing ones. The different steps of this process respond to stimuli that promote the proliferation, migration, and differentiation of endothelial cells, and the degradation of the blood vessel basement membrane and extracellular matrix. 1 This process leads to the sprouting of new microtubes and implies the presence of multiple controls, which can be turned on and off within a short period of time. Angiogenesis is required for physiological processes such as embryonic development, wound healing, tissue and organ regeneration, and for pathological processes such as tumor growth, metastatic dissemination, cardiovascular diseases and diabetic retinopathy. 2 The angiogenic switch depends upon the balance between angiogenic stimulators and inhibitors. 2 Therefore, blocking the action of angiogenic factors, or utilizing angiogenic suppressors to inhibit angiogenesis, constitutes a new strategy to suppress tumor growth. Some angiogenic inhibitors are fragments, or cryptic domains, of larger proteins. This is the case for angiostatin, 3 endostatin, 4 and canstatin, 5 which are proteolytic fragments of plasminogen, collagen XVIII and collagen IV, respectively, and for the 16 kDa Nterminal fragment-derived prolactin 6 or the N-terminal fragment-derived platelet factor 4. 7 The different fragments derived from the five kringles (K) of plasminogen that are known to inhibit angiogenesis have been characterized. Human angiostatin K1-4 (aa 97-454), containing the first four disulfide-linked structures of plasminogen, which was the first protein described, is generated following hydrolysis of plasminogen by a metalloelastase. 3, [8] [9] [10] In vitro, angiostatin K1-4 (aa 97-454) inhibits endothelial cell growth with an ED 50 of 135 nM, 11 and endothelial cell migration in a specific manner. 12 In vivo, angiostatin K1-4 (aa 97-454) inhibits neovascularization in chick chorioallantoic membrane and mouse corneal assays, and suppresses subsequent tumor growth in different murine models. 13 On the other hand, a smaller fragment of plasminogen, containing the first three kringles (K1-3 (aa 97-354)), inhibits endothelial cell proliferation with an ED 50 of 70 nM, but does not display an inhibitory effect on cell migration. In vivo studies have shown that K1-3 (aa 97-354) inhibits tumor growth in different murine models. 14 Another fragment of plasminogen containing only the K5 (aa 481-566) displays distinct inhibitory functions on endothelial cell proliferation with an ED 50 of 50 nM, and on endothelial cell migration. 15, 16 Furthermore, K5 (aa 481-566) and K1-3 (aa 97-354) were shown to cause cell cycle arrest and apoptosis of endothelial cells. 13, 14 It was recently shown that plasminogen can be converted by plasmin (a fibrinolytic serine protease) 17 or by glioma cell BT325-derived proteinase, 18 into a new angiogenic inhibitor, called K1-5 (aa 97-549), which contains the K1-4 and a part of K5 domains of plasminogen. The inhibitory effect of K1-5 (aa 97-549), also called angiostatin 4.5 by other authors, 17 on endothelial cell proliferation appears to be at least 50-fold greater than that of angiostatin K1-4. In vivo, low doses of K1-5 (aa 97-549) suppress angiogenesis in chicken embryo and in mouse corneal assays, whereas angiostatin has no effect at the same dose. Furthermore, daily systemic injections of mice with low doses of K1-5 (aa 97-549) (2 mg/kg) over 18 days, during which K1-4 (aa 97-454) was ineffective, inhibited the growth of, and angiogenesis within, murine T241 fibrosarcomas in mice. Thus, K1-5 (aa 97-549) appears to be a naturally occurring human isoform that is more potent than K1-4 (aa 97-454) in inhibiting the proliferation and migration of endothelial cells in vitro and the T241 fibrosarcoma in vivo. 17 Furthermore, it was recently demonstrated that K1-5 (aa 97-549) mediates apoptosis of vascular endothelial cells by the activation of caspase-3, -8, and -9 activity. 19 Interestingly, the K1-5 (aa 97-549) fragment lacks cysteine residues in positions 555 and 560, thus preventing the formation of two out of three disulfide bonds lying within K5. In order to optimize the antitumor effects associated with the secondary structures of kringle domains, we chose to evaluate the antitumor properties of a fragment that encompasses the first 566 amino acids of plasminogen, allowing the complete secondary structure of the K5.
We constructed a replication-defective adenovirus directing the expression and secretion of the N-terminal fragment of human plasminogen, including K1-5 (AdK1-5(1-566)), and assessed its in vitro and in vivo activity in different murine tumor models. We showed that a single injection of AdK1-5(1-566) into human breast carcinomas resulted in a significant tumor regression, which was complete in 40% of treated animals.
Results
Molecular and functional characterization of AdK1-5(1-566)
The recombinant adenoviruses AdK1-5(1-566) and AdK1-3(1-354) used in this study carry a cytomegalovirus (CMV)-driven N-terminal fragment of human plasminogen that includes all five, or the first three, K domains, respectively, whereas AdCO1 is an 'isogenic' control adenovirus that does not encode any expression cassette (Figure 1a and b) . To characterize the expression of the K1-5 (aa 1-566) and K1-3 (aa 1-354) molecules from the engineered adenovirus, we infected HMEC-1 cells at a multiplicity of infection (MOI) of 300 plateforming units (PFU)/cell for 72 h and analyzed the supernatants by Western blotting. Specific signals were observed from the AdK1-3(1-354)-and AdK1-5(1-566)-infected cell supernatants (Figure 1c) , whereas no signal could be detected following the infection with AdCO1. The immunoreactive peptides appeared with a molecular weight of 40.5 kDa for the K1-3 (aa 1-354) molecule and 63.8 kDa for the K1-5 (aa 1-566) molecule.
To assess in vitro the antiangiogenic effect of AdK1-5(1-566), and to compare its activity to AdK1-3(1-354), human umbilical vein endothelial cells (HUVECs) were infected for 96 h at various MOI (100-800 PFU/cell), and then incubated in the presence of MTT reagent to determine the percentage of surviving cells. In this assay, transduction of HUVEC by AdK1-5(1-566) resulted in a strong and dose-dependent inhibition of endothelial cell surviving (Figure 2a ). AdK1-5(1-566) infection of HUVEC led to a significantly higher inhibitory effect (Po0.001) as compared with cells that had been infected by AdK1-3(1-354). At an MOI of 100 PFU/cell, HUVEC survival of 46720.6 and 88711.9% was observed after infection of HUVEC with AdK1-5(1-566) and AdK1-3(1-354), respectively. Thus, compared to the infection of HUVEC with AdK1-3(1-354), cells were found to be systematically more sensitive to infection with AdK1-5(1-566), with an ED 50 (defined as the MOI leading to 50% inhibition) in the range of 100 PFU/cell, whereas AdK1-3(1-354) was ineffective at this dose. The infection of HUVEC with 800 PFU/cell of AdK1-3(1-354) and AdK1-5(1-566) resulted in cell survival of 5972.8 and 1178.8%, respectively.
The quantities of K1-3 (aa 1-354) and K1-5 (aa 1-566) produced in supernatant of HUVECs 48 h or 96 h postinfection (p.i.) with AdK1-3(1-354) or AdK1-5(1-566) were evaluated with a specific ELISA. The levels of proteins expressed by both adenoviruses were identical, showing that the higher inhibitory effect of AdK1-5(1-566) was related to the specific activity of the K1-5 (aa 1-566) molecule and not to a difference in transgene production ( Figure 2b ). In contrast, infection of HUVEC with the control empty virus had only a marginal effect, even at the highest tested dose of 800 PFU/cell. The dose-dependent inhibitory effect specifically observed after HUVEC infection with AdK1-5(1-566) is thus a direct consequence of peptide expression, and not due to infection with adenovirus per se. This proliferation assay demonstrated that the AdK1-5(1-566) recombinant adenovirus generates a functional secreted peptide, which exhibits a high inhibition of endothelial cell proliferation.
To assess the paracrine potential of K1-3 (aa 1-354) and K1-5 (aa 1-566) molecules to exert these effects, virus-free culture media from virally infected MRC-5 were added to HUVECs. As illustrated in Figure 2c , after 2 or 4 days of exposure and in comparison to the control (supernatant of AdCO1-transduced fibroblasts), we observed a significantly higher inhibition of HUVECs'viability with the supernatant containing the K1-5 (aa 1-566) molecule than with the supernatant containing the K1-3 (aa 1-354) molecule (P ¼ 0.027).
To determine whether K1-3 (aa 1-354) and K1-5 (aa 1-566) affect endothelial cell migration, HUVECs were allowed to migrate in fibronectin-coated Petri dishes in response to vascular endothelial growth factor (VEGF) at a dose of 30 ng/ml after infection at 800 PFU/cell with AdCO1, AdK1-3(1-354) or AdK1-5 (Figure 3a) . In contrast, AdK1-3(1-354) was markedly less active. Following these observations and considering that angiostatin 4.5 (aa 97-549) mediated apoptosis of vascular endothelial cells, 19 we wondered if the difference in activity between AdK1-5(1-566) and AdK3(1-354) on endothelial cells could be explained by the activity of caspase-3, -8 and -9. HUVECs were infected with 800 PFU/cell of AdCO1, AdK1-3(1-354) or AdK1-5(1-566) in the presence of VEGF at a dose of 3 ng/ml. After 48 h, protease activity in the cell lysates was evaluated with caspase-3, -8 and -9 assay kits in two independent experiments. A two-fold increase in caspase-8 was detected 48 h following treatment in AdK1-5(1-566)-and in AdK3(1-354)-treated cells as compared with cells infected with AdCO1 (P ¼ 0.031 and 0.017, respectively, Figure 3b ). Caspase-3 and -9 did not appear to be activated, since no significant difference in caspase-3 and -9 levels was seen between AdCO1-treated cells and cells treated with either AdK1-5(1-566) or AdK1-3(1-354). As such, no significant difference in caspase activation was observed between AdK1-5(1-566) and AdK1-3(1-354) following infection in HUVECs.
AdK1-5(1-566) inhibits tumor growth following intratumoral administration Adenovirus-mediated delivery of K1-3 (aa 1-354) and K1-5 (aa 1-566) peptides was first studied in preestablished human breast (MDA-MB 231) and prostate (PC3) models grown in athymic mice. To this end, experimental xenografts were intratumorally injected with 2 Â 10 9 PFU of AdK1-5(1-566) or AdK1-3(1-354), whereas control animals were intratumorally injected with the AdCO1 control virus or PBS. We followed this protocol for five independent experiments in which mice were randomized and treated when the tumors had reached a mean volume of 62.5715 mm 3 for the PC3 model and 3074 mm 3 for the MDA-MB 231 model. Tumor growth was then monitored until day 20 or 42 postinjection, and the percentage inhibition of tumor growth was calculated. As shown in Figure 4a (Figure 4c ). On hematoxylin-eosin-saffranin (HES)-stained sections, a total absence of tumor was observed in 40% of mice (Figure 4c) , whereas all the animals treated with AdCO1 or AdK1-3(1-354) showed the presence of persistent tumor cells.
AdK1-5(1-566) inhibits angiogenesis following intratumoral administration
A quantitative assessment of angiogenic inhibition induced by AdK1-5(1-566) and AdK1-3(1-354) was performed on the PC3 murine tumor model. Intratumoral Inhibition of the functional intratumoral vascularization induced by AdK1-5(1-566) and AdK1-3(1-354) was evaluated on the MDA-MB 231 model by ContrastEnhanced Color Doppler High-Frequency Ultrasonography (CDHFUS). CDHFUS specifically detects the functional vessels, which is not possible with classical histological techniques. For this study, 120 assays were performed using CDHFUS. The injection of the contrast agent Levovist allowed a precise, weekly quantification of the intratumoral vascularization for the duration of the treatment period (42 days). The resulting data indicated a significant reduction of intratumoral vascularization (88.7711.3% at week 5 and 61710% at day 42, Po0.05) within the tumors from the AdK1-5(1-566)-treated group as compared with tumors from the AdCO1 group (Figure 6a and b) . Thus, we demonstrated, using an innovative method, that the antitumoral effect of the AdK1-5(1-566) is correlated with an antiangiogenic activity.
Systemic administration of AdK1-5(1-566)
To test whether secreted K1-5 (aa 1-566) can function in a paracrine manner, we assessed the systemic administration of AdK1-5(1-566) and AdK1-3(1-354) in order to infect a wide range of tissues that are able to secrete angiostatic factors. After systemic administration, 
Discussion
Tumor-secreted angiostatin has been shown to be a physiopathological inhibitor of angiogenesis, driving metastases into a dormant state. However, subcutaneous and intraperitoneal bolus injections of human angiostatin have highlighted pharmacological issues as angiostatin is rapidly cleared from the circulation. Furthermore, its serum half-life is rather limited in immunocompetent C57Bl/6 mice, 20 raising the possibility that such a high clearance rate may be a direct consequence of its low molecular weight and efficient renal filtration. A prolonged exposure of purified angiostatin at high doses has been shown to be required to maintain cytostatic intratumoral concentrations of angiostatin. 21 The direct transduction of the tumor and the surrounding tissue with a recombinant virus encoding the angiostatin cDNA, or systemic delivery of the vector, may thus represent a more efficient method of achieving constant long-lasting intratumoral or systemic concentrations of angiostatin. In this context, we previously reported that a single, local injection of a replication-defective adenovirus encoding a secretable angiostatin-like molecule (AdK1-3(1-354) ) into small (20 mm 3 ) xenografts could suppress subsequent tumor growth. 22 On the other hand, we documented that the effects were only marginal when AdK1-3(1-354) was intratumorally or systemically injected into larger tumors (420 mm 3 ). 23, 24 This is supported by a study in which bolus injections of the angiostatin protein were reported to exert very different antitumor effects depending on the developmental stage of experimental carcinogenesis in a pancreatic murine tumor model. 25 These authors documented that endstage pancreatic tumors were resistant to both angiostatin and endostatin in mice. In contrast, TNP-470, a synthetic analogue of fumagillin, and the combination of angiostatin and endostatin, produced significant tumor regression of large tumors, highlighting the fact that the use of angiogenic inhibitors could become a plausible and important component of anticancer treatment strategies. Nevertheless, these observations emphasize the need to discover new antiangiogenic molecules that Since the K5 (aa 481-566) of plasminogen, which is not present in the originally described isoforms (K1-3 (aa 97-354) or K1-4 (aa 97-454)), has been shown to be a key functional domain, which possesses potent antiangiogenic activity, we have chosen to focus on new plasminogen-derived isoforms consisting of K1-5 domains including the C-terminal regions of K5 (aa 481-566). To this end, we have constructed a replicationdefective adenovirus (AdK1-5(1-566)) that expresses a new N-terminal (aa 1-566) form of human plasminogen, which includes the preactivation peptide and full K1-5, and comprises the three cysteine residues in positions 543, 555 and 560, allowing the formation of the three disulfide bonds lying within the K5 (aa 481-566). In our study, we have assessed the antiangiogenic activity of the K1-5 (aa 1-566) molecule in vitro and in vivo in different murine tumor models in comparison to AdK1-3(1-354), an adenovirus expressing the N-terminal fragment of plasminogen containing the first three complete kringles (K1-3 (aa 1-354) ).
Our findings demonstrate that the inclusion of the K4 (aa 355-454) and the K5 (aa 481-566) domains in the K1-3 (aa 1-354) molecule considerably increased its anti-angiogenic activity, as AdK1-5(1-566)-infected 1-354) and K1-5(1-566) selectively induce endothelial cells to undergo a cell death that is biochemically identical to apoptosis. We also performed a cell viability assay with HUVECs infected with 800 PFU/cell of AdK1-5(1-566), AdK1-3(1-354) or AdCO1 for 96 h in the presence or absence of caspase-3-, -8 or -9 inhibitors. This assay also demonstrated that the caspase-8 inhibitor blocks the K1-5 effect on cell viability of the HUVECs more efficiently than the caspase-3 and -9 inhibitors (data not shown).
Despite their structural similarity and sequence homology, K domains appear to have distinct inhibitory profiles in endothelial cell migration assays. We have shown that K1-5 (aa 1-566) molecule is a potent inhibitor of endothelial cell migration, implying that both K4 (aa 355-454) and/or K5 (aa 481-566) may be necessary for the antiendothelial cell activity of the protein. In contrast, AdK1-3(1-354)-infected HUVEC had only little activity on endothelial cell migration. Many previous studies have suggested that the functional elements for the inhibition of migration may reside on both the K4 (aa 355-454) and K5 (aa 481-566) domains. 12, 16 Considering that neovascularization is required for tumor growth in vivo, we wondered whether the marked responsiveness of endothelial cells to AdK1-5(1-566) that was observed in vitro would induce more pronounced antitumoral effects than those exhibited by AdK1-3(1-354). Three different experimental models (human MDA-MB-231 breast carcinoma, human PC3 prostatic carcinoma and murine B16 F10 melanoma) and two different routes of adenoviral delivery (ie intratumoral and intravenous) were employed. We have shown that these three models are quite different with regard to their levels of VEGF production and growth when established after subcutaneous (s.c.) injection into nude mice (data not shown).
A single intratumoral injection of AdK1-5(1-566) was shown to inhibit primary tumor growth in two wellestablished (420 mm 3 ) xenograft murine models (human MDA-MB-231 breast carcinoma and human PC3 prostatic carcinoma), and this effect was not observed with AdK1- 3(1-354) . In all cases, AdK1-5(1-566) displayed a more potent effect on tumor growth than AdK1-3(1-354), since the percentage of tumor growth inhibition was constantly increased in the AdK1-5(1-566)-injected group. The antitumoral effect was more apparent in the case of the MDA-MB-231 model, since marked inhibition of tumor growth became very pronounced when AdK1-5(1-566) was injected, and 40% of the tumors had totally regressed only in the AdK1-5(1-566)-treated group. Interestingly, the AdK1-5(1-566)-transduced MDA-MB-231 tumors apparently failed to establish a vascular network within the tumor mass in order to support rapid and extensive growth, and this failure translated into a 490% inhibition of tumor growth. For this model, the number of functional intratumoral vessels was calculated by CDHFUS analysis after injection of the D-galactose-based contrast agent Levovist. Treatment efficacy was evaluated by monitoring tumor size and percentage of tumor growth inhibition until day 42 postinjection of adenovirus. The resulting data indicated a significant reduction (460%, Po0.05) of intratumoral vascularization within the tumors from the AdK1-5(1-566)-treated group, which was correlated with significant tumor growth inhibition (490%, Po0.05). PECAM-1 immunostaining of PC3 tumor sections also revealed a significant reduction of neoangiogenesis in the AdK1-5(1-566)-treated tumors, which was more pronounced than in the case of tumors treated with AdK1-3(1-354). Well-formed vessels with a mature lumen were observed in control PC3 tumors, but never in AdK1-5(1-566)-treated tumors.
In addition, we showed that the systemic injection of AdK1-5(1-566) delayed MDA-MD-231 tumor establishment, which highlights the paracrine activity of secreted K1-5 (aa 1-566). In contrast, the systemic injection of AdK1-3(1-354) had no effect on tumor growth, and was similar in the AdCO1-treated mice, demonstrating that K1-5 (aa 1-566) yields stronger antiangiogenic activity than K1-3 (aa 1-354). Furthermore, we provide evidence that AdK1-5(1-566), and not AdK1-3(1-354), could strongly interfere with tumor cell dissemination in the B16-F10 C57Bl/6 syngenic model, by restricting tumor cell access to the vasculature.
Our results clearly show that K1-5 (aa 1-566) is a very potent therapeutic candidate to target tumor angiogenesis. It has a more potent effect in inhibiting angiogenesis and tumor growth, because it displays a stronger effect on endothelial cell growth and motility, and possesses a longer half-life in vivo, than K1-3 (aa 1-354), due to its increased molecular weight, as described previously. 17 To date, it has been shown that limited proteolysis of plasminogen leads to the generation of several isoforms of endothelial growth inhibitors, which have a different range of activity including inhibition of endothelial cell proliferation, migration and induction of apoptosis. To date, it seems that K1-3 (aa 97-354) is at least as potent as angiostatin K1-4 (aa 97-454) in suppression of endothelial cell growth, 11 and that K5 (aa 481-566) and angiostatin 4.5 (aa 97-549) appear to be more potent than angiostatin K1-4 (aa 97-454) in vitro and in vivo. [15] [16] [17] More recently, it was shown that angiostatin 4.5 (aa 97-459) initiates a cascade of protease activation events involving caspase-3, -8 and -9. 19 In our study, we have shown that K1-5 (aa 1-566) displays a more potent effect on suppression of endothelial cell growth and migration, but displays no significant difference regarding caspase activation versus K1-3 (aa 1-354). It has been shown that an endothelial cell protein, angiomotin, has a role in mediating migration, and that binding of K1-4 (aa 97-454) to angiomotin inhibits endothelial cell migration. 26 Thus, it is plausible that K1-5 (aa 1-566) binds angiomotin more strongly than K1-3 (aa 1-354), and
therefore inhibits the migration in vitro of the endothelial cells more potently. With regard to molecular mechanisms underlying the angiostatic actions of the K structures, there are still questions that remain to be clarified. In particular, it is not known whether there are one or more endothelialspecific receptors for the different isoforms. It appears that K5 (aa 481-566) and other isoforms such as K1-4 (aa 97-454) may act through separate pathways because it has been shown that K1-4 (aa 97-454) and K5 (aa 481-566) synergistically suppress endothelial cell growth in vitro. Therefore, we believe that K1-5 (aa 1-566) and K1-3 (aa 1-354) could differentially activate both pathways and/or use other endothelial cell signals such as integrins, 27 focal adhesion kinases 28 or ATP synthases 29 on the surface of endothelial cells. Angiostatic therapy using recombinant adenoviruses has been shown to be experimentally plausible and efficient. Nevertheless, the failure of both whole angiostatin protein and a protein composed of only the first three K domains to abolish tumorigenesis underlines the importance in discovering and evaluating new antiangiogenic molecules. In our study, we have clearly shown that the K1-5 (aa 1-566) is a better candidate than K1-3 (aa 1-354) for such a role, as K1-5 (aa 1-566) has been shown to display a potent effect on the suppression of endothelial cell growth, tumor growth and metastatic dissemination. It would be interesting to compare the new fragment K1-5 (aa 1-566) with other plasminogenderived fragments such as angiostatin 4.5 (aa 97-549) or K5 (aa 481-566). Adenovirus-mediated delivery of K1-5 (aa 1-566), or purified K1-5 (aa 1-566) protein, may become a potential clinical treatment of cancer patients, or be used as prevention therapy for metastatic development.
Materials and methods

Construction, propagation and infection of recombinant adenoviruses
AdK1-5(1-566) and AdK1-3(1-354) are both replicationdefective recombinant E1E3-deleted adenoviruses directing the expression and secretion of plasminogen-derived factors (including the signal peptide), under the control of the human CMV immediate-early promoter. AdK1-5(1-566) expresses the N-terminal fragment of human plasminogen (up to residue 566) containing K1-5, and AdK1-3(1-354) expresses the N-terminal fragment of human plasminogen (up to residue 354) containing K1-3.
22
DNA fragments encoding K4 and K5 were generated by PCR from plasminogen cDNA, and were inserted into the shuttle plasmid pMP13 20 between the N-terminal fragment of plasminogen (containing the 18 amino-acid signal peptide of plasminogen followed by K1-3) and the SV40 late polyadenylation signal. The resulting Km RSacB-ColE1 plasmid carrying the K1-5 expression cassette under the control of CMV promoter is bordered by the left end of the Ad5 genome (nucleotides 1-386) and part of the Ad pIX gene (nucleotides 3446-4296), which facilitates homologous recombination with plasmid pXL3215b.
20 pXL3215 contains the Ad5 genome deleted for E1 (nucleotides 1-386), E3 (nucleotides 28592-30470), and bordered by two PacI sites. A plasmid encoding a recombinant adenoviral genome bearing K1-5 was generated by homologous recombination between the shuttle plasmid and pXL3215 in Escherichia coli, as described previously. 30 After recombination, the adenoviral genome is excised by PacI digestion. Recombinant adenoviruses (AdK1-5(1-566)) were obtained following Lipofectamine Plus-mediated transfection of 293 cells with PacI-digested DNA (Lipofectamine Plus s , Life Technologies Inc.). AdCO1 is a control E1E3-deleted adenovirus that does not bear an expression cassette in place of the E1 genes. AdK1-5(1-566), AdK1-3(1-354) and AdCO1 were further amplified in 293 cells and purified by two-step CsCl gradient ultracentrifugation. Viral titers were quantified both as viral particles (vp)/ml by DNA measurement by high-performance liquid chromatography analysis and as PFU/ml following infection of 911 cells. Typical titers were obtained for the viruses used in this work: AdK1-3 (1-354), 2.4 Â 10 11 PFU/ml (4.12 Â 10 12 vp/ml); AdK1-5(1-566), 2.8 Â 10
11 PFU/ml (4.86 Â 10 12 vp/ml); AdCO1, 3.6 Â 10 11 PFU/ml (6.18 Â 10 12 vp/ml). Thus, for the viruses used in the following experiments, viral quantification showed that 1 PFU is equivalent to 17.2, 17.4 and 17.1 vp for AdK1-3(1-354), AdK1-5(1-566) and AdCO1, respectively.
Cell lines
HUVECs were cultured in EBM-2 medium (Clonetics) as recommended by the manufacturer. PC3 cells were cultured in Ham's F12 with 10% fetal calf serum (FCS), 1 mM L-glutamine and 1.5 g/l sodium bicarbonate. The MDA-MB-231 human breast carcinoma and the B16-F10 mouse melanoma cell lines were cultured in DMEM with 10% FCS, 1 mM L-glutamine and 1.5 g/l sodium bicarbonate. HEK 293 and HMEC-1 cells were harvested, as described previously.
22,31
Western blot analysis Subconfluent HMEC-1 cells were infected with AdK1-5(1-566), AdK1-3(1-354) and AdCO1 at MOI of 300 PFU/cell. Cell culture supernatants were collected 72 h p.i.. In all, 100 mg of protein from each sample was run on a NuPage MOPS 10% gel (Novex, San Diego, USA) before being transferred onto a 0.45 mm nitrocellulose membrane (Schleicher and Schuell). As a control, 100 ng of human plasminogen (Stago, Asnières, France) were coelectrophoresed with all samples. After overnight incubation in blocking buffer (Tris 1 mM (pH 8), 150 mM NaCl, 0.05% Tween 20, 5% nonfat dry milk), the membranes were incubated for 3 h with anti-human plasminogen monoclonal antibody A1D12. 23 Membranes were washed in TBS-0.05% Tween 20 and incubated for 1 h with a horseradish peroxidase-conjugated goat anti-mouse antibody (Biosys, Compiegne, France). After washing, localization of antibody-hybridized complexes on the membranes was performed with enhanced chemiluminescence ECL Plus kit (Amersham).
Cell viability assay
HUVECs were seeded at a density of 5 Â 10 3 cells in 24-well tissue culture dishes. After 24 h, HUVECs were starved in EBM-2 medium supplemented with 0.2% FCS for 24 h. An optimal stimulatory concentration of 3 ng/ml for VEGF was used for all viability experiments. To ascertain the AdK1-5(1-566) dose yielding 50% of K1-5 (aa 1-566) gene transfer A Galaup et al inhibition (ID 50 ), a survival test was performed after 96 h of treatment for two independent experiments. Endothelial cells were infected with AdK1-5(1-566), AdK1-3 or AdCO1 at an MOI of 100, 300, 600 and 800 PFU/ cell (n ¼ 6 for each condition) in 250 ml of medium supplemented with 2% FCS for 4 h, before the addition of 500 ml of culture medium supplemented with 2% FCS. In each experiment, an internal control (ie cells that were mock treated) was included in each culture plate. Cell survival was quantified by a cell viability assay using MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide -Sigma), as described previously. 24 The percentage of viable cells was calculated by comparing the OD of the samples with those incubated with noninfected cell supernatants.
In addition, a cell viability assay was performed with HUVECs using supernatant of AdK1-5(1-566), AdK1-3(1-354) or AdCO1-transduced human fibroblasts (MRC-5 cells). MRC-5 cells were infected with a dose of 800 PFU/cell for 4 h. Viruses were then removed by washing the cells three times with PBS. MEM supplemented with 5% of SVF was then added to the vials and supernatants were collected 96 h after infection and exposed for 30 min to ultra-violet light in order to completely inactivate the virus. In this assay, HUVECs were seeded at a density of 5 Â 10 3 cells in 24-well tissue culture dishes and after 24 h were incubated with 400 ml of EBM-2 medium supplemented with 3 ng/ml of VEGF and 400 ml of each supernatant. After 96 h, the cells were quantified with a cell viability assay using MTT compound. 1-566) or AdCO1 at an MOI of 300 PFU/cell in 250 ml of medium for 2 h, before adding 500 ml of culture medium. Noninfected cells were included in each culture plate as control. The culture supernatants were collected and the cells counted 48 and 96 h p.i. For each analysis, samples were diluted to 1:10 and run with the standards in duplicate. For the quantification, a solid-phase ELISA was used as described previously. 24 
Migration assays
For the migration assay, HUVECs were seeded at a density of 2 Â 10 5 cells in EBM-2 medium supplemented with 2% FCS in fibronectin-coated (10 mg/ml) Petri dishes (35 mm diameter) the day before viral infection. Migration assays were performed in triplicate in two independent experiments as described previously. 32 HUVECs were infected with AdK1-5(1-566), AdK1-3(1-354) or AdCO1 at an MOI of 800 PFU/cell in 500 ml of medium supplemented with 0.2% FCS for 4 h. The cells were then washed and a 'scratch wound' was created by scraping the cell monolayer with a sterile pipette tip, followed by the addition of culture medium supplemented with 0.2% FCS and 30 ng/ml of VEGF. Every 24 h for a 4-day period, migration was quantified by counting cell numbers at indicated migration distances from the wound edge.
Caspase activity
To assess intracellular caspase activity, HUVECs seeded at 5 Â 10 5 cells in six-well tissue culture dishes were starved 24 h postseeding in EBM-2 media supplemented with 0.2% FCS for a 24 h period. An optimal stimulatory concentration of 3 ng/ml for VEGF was used for all the caspase experiments. To compare the AdK1-5(1-566) and AdK1-3(1-354), a caspase activity assay was performed for two independent experiments. Endothelial cells were infected with AdK1-5(1-566), AdK1-3(1-354) or AdCO1 at 800 PFU/cell in 3 ml of medium supplemented with 2% FCS. In each experiment, 50 nM of staurosporine was included as a positive control. After 48 h, cells were resuspended in 50 ml of cell lysis buffer, and the protease activity of the lysates was evaluated by caspase-3, -8, and -9 Fluorometric Assay Kits (R&D Systems, Minneapolis, MN, USA). The lysates were diluted 1:2 in reaction buffer and incubated with the caspase-3 (-8 or -9)-specific peptides conjugated to 7-amino-4-trifluromethyl coumarin at 371C. After 2 h of incubation, the optical density was determined using a microplate reader set at 405 nm. Bradford protein assays were performed on each lysate to normalize the OD unit value and results are expressed as OD (405 nm) for 100 mg of proteins.
To evaluate the antimetastatic activity of K1-5 (aa 1-566), mice (n ¼ 6-7) received one i.v. injection of 5 Â 10 9 PFU of AdK1-5(1-566), AdK1-3(1-354) or AdCO1 in a volume of 100 ml of PBS via the retro-orbital sinus. After 24 h, cultured B16-F10 melanoma cells were harvested, washed and resuspended in PBS at 2 Â 10 5 cells/ml, of which 100 ml were injected i.v. via the retroorbital sinus of 8-week-old syngenic C57Bl/6 mice. At 10 days after tumor cell injection, animals were killed, their lungs excised and the number of metastases counted under a dissecting microscope. For all the experiments, a Student's t-test was used for statistical analysis.
In vivo quantification of human K1-3 (aa 1-354) and K1-5 (aa 1-566)
In order to detect K1-3 (aa 1-354) and K1-5 (aa 1-566) in tumors after viral local administration, PC3-and MDA-MB-231-derived tumors were collected and immunostained for human angiostatin, respectively, 6 and 42 days after the injection of the adenovirus. For angiostatin immunohistochemistry, samples were fixed in Finefix (Microm). Heat-induced epitope retrieval in 10 mmol/l citrate buffer (pH 6.0) was performed. After quenching of endogenous peroxidase activity, sections were incubated with goat anti-angiostatin primary antibody (R&D systems, 1:50) for 1 h and processed with biotinylated rabbit anti-goat secondary antibody (1:50) for 30 min, followed by streptavidin-horseradish peroxidase (1:100, Dako) 30 min. Slides were treated with DAB chromogenic substrate (Microm) for 10 min and counterstained with Mayer's hematoxylin and mounted. To quantify the amount of K1-3 (aa 1-354) and K1-5 (aa 1-566) in mice sera after viral systemic administration, blood samples were collected 8 days after adenovirus delivery, from AdK1-3(1-354)-and AdK1-5(1-566)-injected mice, sera from PBS-and AdCO1-injected mice were systematically included as controls. For each analysis, samples were diluted to 1:100 and run with the standards in duplicate. For the quantification, a solid-phase ELISA was used, as described previously. 24 
Quantification of angiogenesis
To evaluate the antiangiogenic effect of AdK1-5(1-566) and AdK1-3(1-354), PC3 tumors with mean volumes of 62.5715 mm 3 or MDA-MB 231 tumors with mean volumes of 3074 mm 3 were injected at day 0 with a single injection of 2 Â 10 9 PFU of AdK1-5(1-566), AdK1-3(1-354) or AdCO1 in a volume of 50 ml of PBS.
PC3-derived tumors were collected when their volumes had reached mean values of 524724 mm 3 in order to limit necrosis and to improve the image analysis for vessel quantification. Following fixation of the tumors in absolute ethanol, paraffin sections (4 mm thick) were prepared and stained with HES. PC3-derived tumors were immunostained for murine CD31 (PECAM-1) and analyzed using a Zeiss Axiophot microscope (Germany) and a Sony 3CCD camera as described previously. 24 For each animal, a representative histological sample immunostained for murine CD31 was submitted to image analysis using a Zeiss Axiophot microsope (Germany) and a Sony 3CCD camera (resolution 768 Â 576 pixels). The choice of a Â 100 magnification enabled a digitization of nearly the whole specimen in all cases (eight contiguous fields, excluding necrotic and fibrotic areas).
Images were then analyzed with a Linux-based specially developed program, producing a quantitative index from 0 to 255. Digitalized color images were transformed into various gray-level images. A theoretical image exclusively composed of red-brown vessels would correspond to an index of 255, whereas an image totally devoid of vessels (entirely stained blue) is associated with an index of 0. Each pixel of the image is associated with a figure between 0 and 255 and a mean value of all pixels is obtained for each image. The final index (score) for each animal is obtained by calculating the mean value of the eight contiguous fields.
CDHFUS was used in order to evaluate inhibition of tumor angiogenesis for the MDA-MB-231 tumors model. Weekly examinations were performed on MDA-MB-231 tumors (five for control or AdK3(1-354)-treated mice and six for AdCO1-or AdK1-5(1-566)-treated animals) after the beginning of treatments (day 2) for a total of 6 weeks (day 42) with CDHFUS. Examinations were performed with an ATL-HDI 5000 sonograph using a 12 MHz linear probe. For all the 120 investigations, sonograph settings remained unchanged within the 6 weeks of examinations. For each investigation, the protocol was: (1) in color Doppler mode after contrast agent (Levovist, Schering) injection; (2) counting of the number of intratumoral vessels visualized by a color scale on the 2D maximal transversal scan of the tumor. Vessels are colored in red (inversely in blue) when the flow direction inside the vessel arrives toward (respectively, moves away from) the ultrasound beam. The color intensity, in each red or blue scale, depends on the mean velocity module inside the vessel. After 6 weeks, all the MDA-MB-231-derived tumors were collected and stained with HES.
